News and Trends 1 Feb 2015
Phenex sells out its main programme to Gilead
Gilead Sciences announces the acquisition of Phenex Pharmaceuticals’ development program for non-alcoholic steatohepatitis (NASH) and other liver diseases. Gilead Sciences and Phenex Pharmaceuticals announced the signing of a definitive agreement…